 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || RC98 / Rongchang Pharma
PK/PD data, Preclinical, Journal: Preclinical Pharmacokinetics and Pharmacology Study of RC98: A Programmed Cell Death Ligand 1 Monoclonal Antibody in Cynomolgus Monkeys. (Pubmed Central) - Apr 16, 2024
These data indicate that the immune system was clearly activated. In addition, the non-clinical data could provide a basis for its efficacy evaluation in clinical trials.
- | Aidixi (disitamab vedotin) / Pfizer, RC98 / Rongchang Pharma
Trial primary completion date, Metastases: To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) (clinicaltrials.gov) - Dec 18, 2023
P1, N=24, Recruiting, Sponsor: RemeGen Co., Ltd.
In addition, the non-clinical data could provide a basis for its efficacy evaluation in clinical trials. Trial primary completion date: Dec 2023 --> May 2024
- || RC98 / Rongchang Pharma
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: A Study of RC98 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov) - Nov 27, 2023
P1, N=63, Active, not recruiting, Sponsor: RemeGen Co., Ltd.
Trial primary completion date: Dec 2023 --> May 2024 Recruiting --> Active, not recruiting | N=25 --> 63 | Trial primary completion date: Dec 2022 --> Dec 2023
- || Aidixi (disitamab vedotin) / Pfizer, RC98 / Rongchang Pharma
Enrollment open, Metastases: To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) (clinicaltrials.gov) - Oct 18, 2022
P1, N=24, Recruiting, Sponsor: RemeGen Co., Ltd.
Recruiting --> Active, not recruiting | N=25 --> 63 | Trial primary completion date: Dec 2022 --> Dec 2023 Not yet recruiting --> Recruiting
- || Aidixi (disitamab vedotin) / Pfizer, RC98 / Rongchang Pharma
New P1 trial, Metastases: To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) (clinicaltrials.gov) - Aug 24, 2022
P1, N=24, Not yet recruiting, Sponsor: RemeGen Co., Ltd.
- | RC98 / Rongchang Pharma
Trial completion date, Trial primary completion date, Metastases: A Study of RC98 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov) - Mar 8, 2022
P1, N=25, Recruiting, Sponsor: RemeGen Co., Ltd.
Not yet recruiting --> Recruiting Trial completion date: Mar 2022 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
- | RC98 / Rongchang Pharma
Trial completion date, Trial primary completion date, Metastases: A Study of RC98 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov) - Nov 29, 2021
P1, N=25, Recruiting, Sponsor: RemeGen Co., Ltd.
Trial completion date: Mar 2022 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Nov 2021 --> Mar 2022 | Trial primary completion date: Aug 2021 --> Dec 2021
- || RC98 / Rongchang Pharma
Enrollment open, Trial completion date, Trial primary completion date, Metastases: A Study of RC98 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov) - Apr 27, 2021
P1, N=25, Recruiting, Sponsor: RemeGen
Trial completion date: Nov 2021 --> Mar 2022 | Trial primary completion date: Aug 2021 --> Dec 2021 Not yet recruiting --> Recruiting | Trial completion date: Apr 2021 --> Nov 2021 | Trial primary completion date: Feb 2021 --> Aug 2021
- || RC98 / Rongchang Pharma
New P1 trial, Metastases: A Study of RC98 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov) - Dec 8, 2019
P1, N=25, Not yet recruiting, Sponsor: RemeGen